6-9 September 2018 | Kaohsiung, Taiwan

20th Asia Pacific League of Associations for Rheumatology Congress

6-9 September 2018 | Kaohsiung, Taiwan

Recent Updates on Inteleukin-6 signal blocking therapy for Autoimmune Diseases including RA

In this morning symposium during APLAR 2018, a famous Japanese, Taiwanese and Koreans physicians will discuss treatment strategy for Rheumatoid Arthritis (RA) and autoimmune diseases such as large vessel vasculitis as a brand-new indication of Tocilizumab (TCZ), which is a monoclonal anti- Interleukin-6 (IL-6) receptor antibody.
TCZ is well known to exert efficacy regardless of combination with Methotrexate (MTX) in RA patients, and recent data also demonstrates that TCZ has a potential to withdraw not only MTX but also TCZ itself. Moreover, TCZ safety evidence is also accumulating. The long term extension of a single-arm, observational post marketing surveillance study in Japan shows that TCZ did not increase fatal events, serious infection, malignancy, GI perforation, or serious cardiac dysfunction over 3 years.
TCZ is also approved as a treatment for Large Vessel Vasculitis (LVV) such as Giant Cell Arteritis (GCA) and Takayasu Arteritis in several countries. The GiACTA Study, which is multicenter, prospective randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of TCZ in GCA patients, shows that TCZ makes patients possible to reduce or withdraw glucocorticoids (GCs), and provide better quality of life by releasing side effects related to GCs.
Through each speaker’s fruitful lecture, the audiences will cover updated information of the possibilities of IL-6 signal blocking and expert’s opinions for autoimmune diseases including RA.
Moderators
Prof. Wen-Chan Tsai, Taiwan
Prof. Sang-heon Lee, Korea
Speakers
Prof Kazuhiko Yamamoto, Emeritus Professor The University of Tokyo
Prof Tsutomu Takeuchi, Professor of Rheumatology, Department of Internal Medicine, Keio University School of Medicine in Tokyo, Japan
Prof Yoshiya Tanaka, Professor and Chairman of the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
Prof Der-Yuan Chen, Vice Superintendent, China Medical University Hospital